AngioDynamics price target raised to $17 from $15 at Canaccord

Canaccord analyst John Young raised the firm’s price target on AngioDynamics (ANGO) to $17 from $15 and keeps a Buy rating on the shares. The firm said the company had another well-executed quarter, driven by growth in its Med-Tech business with nice beats across the board. Med-Tech, Med-Device, total revenues, adj. EBITDA and adj. EPS all beat estimates, capping off a momentum-building year for the company and there wasn’t much thesis changing news for the company during the quarter.